Aelis Farma SA
Research Aelis Farma SA (AELIS) on Bullrun: market cap EUR 13.91M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerAELIS
- ExchangePA
- CountryFrance
- SectorHealthcare
- IndustryBiotechnology
- CurrencyEUR
- Market capEUR 13.91M
- Financial periodFY2025
- RevenueEUR 0
- Revenue growth-100.0%
- Net income-EUR 6.43M
- Free cash flow-EUR 5.36M
Valuation Snapshot
latest market cap is EUR 13.91M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | EUR 0 | -EUR 6.43M | -EUR 5.36M | n/a | -0.47 | EUR 8.21M | EUR 6.61M | EUR 4.44M |
| FY2024 | EUR 2.68M | -EUR 7.46M | -EUR 12.02M | n/a | -0.55 | EUR 14.05M | EUR 6.09M | EUR 10.12M |
| FY2023 | EUR 9.05M | -EUR 5.08M | -EUR 13.05M | n/a | -0.39 | EUR 20.23M | EUR 4.04M | EUR 13.20M |
| FY2022 | EUR 3.81M | -EUR 14.29M | -EUR 13.19M | n/a | -1.21 | EUR 34.40M | EUR 3.82M | EUR 19.79M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-27 | EUR 13.91M | n/a | n/a | 0 |
Dividend history
Latest trailing dividend snapshot: annual dividend/share 0 EUR.
About Aelis Farma SA
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France. The company owns a pipeline of pharmacological inhibitors, including AEF0117, a drug candidate, which is in Phase 2b clinical trials for the treatment of the harmful effects of excessive cannabis use; AEF0217, a drug candidate, which is in phase 1/2 clinical trials to treat cognitive deficits observed in down syndrome;
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Aelis Farma SA's market cap?
Aelis Farma SA's market capitalization is EUR 13.91M.
What does Aelis Farma SA do?
Aelis Farma SA, a clinical-stage biopharmaceutical company, focuses on discovering and developing drug candidates for the treatment of central nervous system disorders in France.